Back

Differential impact of milvexian, an investigational oral FXIa inhibitor vs apixaban and dabigatran on thrombin generation in human donor plasma in vitro

28 August 2022 (11:15 - 12:00)
Organised by:
Congress Presentation Part of: Clinical and basic science insights in vascular disease Thrombosis, Bleeding ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Madhu Chintala

Spring House (United States of America)

6 More presentations in this session

Presentation thumbnail
Genome-wide association study on cerebral white-matter hyperintensities in 36,577 individuals
Mr J. Jespersen (Copenhagen, DK)
Abstract Slides
Presentation thumbnail
DNA damage induced by radiation exposure from cardiac catheterization - an analysis in patients and operators
Doctor T. Ishida (Fukushima, JP)
Abstract Slides
Presentation thumbnail
SWATH proteomic analysis from the standard care versus celecoxib outcome trial identifies renal biomarkers are associated with early cardiovascular events amongst NSAID users
Doctor R. Vaja (London, GB)
Abstract Slides
Presentation thumbnail
Preservation of vasculature is beneficial in mitigating cisplatin induced acute kidney injury
Associate Professor H. Pan (Saint Louis, US)
Abstract Slides
Presentation thumbnail
Lack of PI 3-kinase isoform p110alpha impairs SMC differentiation and proliferation and promotes aortic aneurysm formation
Doctor M. Vantler (Cologne, DE)
Abstract Slides

Access the full session

Session thumbnail
Clinical and basic science insights in vascular disease

The Event

Event poster

ESC Congress 2022

28 August 2022 11:15 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources